Tavotek Biotherapeutics
Gwynedd
About Tavotek Biotherapeutics
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect (an innovative Phage Display Library), TavoPrecise (engineering platform for tissue-specific biologics), and TavoMIP (a multicyclic peptide platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $55.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2021)
- Website: tavotek.com#
- Phone: 267-405-9426
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/tavotek-biotherapeutics-40191 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.